➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Mallinckrodt
Baxter
Colorcon
Moodys

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

CARDURA XL Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Cardura Xl, and what generic alternatives are available?

Cardura Xl is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in CARDURA XL is doxazosin mesylate. There are fourteen drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.

US ANDA Litigation and Generic Entry Outlook for Cardura Xl

A generic version of CARDURA XL was approved as doxazosin mesylate by APOTEX on October 18th, 2000.

  Start Trial

Drug patent expirations by year for CARDURA XL
Drug Prices for CARDURA XL

See drug prices for CARDURA XL

Drug Sales Revenue Trends for CARDURA XL

See drug sales revenues for CARDURA XL

Recent Clinical Trials for CARDURA XL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Brown UniversityPhase 2
University of California, Los AngelesPhase 3
Ralph H. Johnson VA Medical CenterPhase 1/Phase 2

See all CARDURA XL clinical trials

Pharmacology for CARDURA XL

US Patents and Regulatory Information for CARDURA XL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer CARDURA XL doxazosin mesylate TABLET, EXTENDED RELEASE;ORAL 021269-001 Feb 22, 2005 RX Yes No   Start Trial   Start Trial   Start Trial
Pfizer CARDURA XL doxazosin mesylate TABLET, EXTENDED RELEASE;ORAL 021269-002 Feb 22, 2005 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Moodys
Colorcon
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.